E-GEOD-33625 - Distinct effects of topoisomerase II inhibitors on tumor cell lines (part 2)

Status
Released on 4 June 2013, last updated on 2 June 2014
Organism
Homo sapiens
Samples (4)
Array (1)
Protocols (7)
Description
One major class of anti-cancer drugs targets topoisomerase II to induce DNA double-strand breaks and cell death of fast growing cells. Here, we compare three members of this class - the antracyclines doxorubicin and aclarubicin, and a chemically unrelated compound, etoposide. Aclarubicin does not induce DNA breaks. We define a new activity for the antracyclines: unsupported histone eviction from ´open´ or loosely packed chromosomal areas reflecting exon and promoter regions. As a result, the epigenome and the transcriptome are strongly affected. Tissue culture cells were treated with doxorubicin, aclarubicin or etoposide for 2 hours. Then drugs were removed by extensive washing. cells were further cultured for indicated days before total RNA were extracted and compared to un-treated control.
Experiment type
transcription profiling by array 
Contacts
Baoxu Pang <geo@ncbi.nlm.nih.gov>, Arno Velds, Jacques Neefjes, Ron Kerkhoven
Citation
MIAME
PlatformsProtocolsFactorsProcessedRaw
Files
Investigation descriptionE-GEOD-33625.idf.txt
Sample and data relationshipE-GEOD-33625.sdrf.txt
Processed data (1)E-GEOD-33625.processed.1.zip
Array designA-MEXP-1173.adf.txt
Links